Back to Search
Start Over
Treatment of the Primary Tumor in Anal Canal Cancers.
- Source :
-
Surgical oncology clinics of North America [Surg Oncol Clin N Am] 2017 Jan; Vol. 26 (1), pp. 73-90. - Publication Year :
- 2017
-
Abstract
- Radical concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C (MMC) remains the standard of care for squamous cell carcinoma of the anus. Phase III trials over 2 decades have used combined radiation doses of 50 to 60 Gy with concurrent fluoropyrimidines, MMC, or cisplatin in various doses and schedules. Modern radiotherapy techniques allow the production of highly conformal plans, decreasing radiation doses to the organs at risk and ensuring a shorter overall treatment time without the need for treatment breaks. These techniques offer the potential to improve compliance and even escalate doses of radiation.<br /> (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Subjects :
- Anal Canal physiopathology
Anal Canal radiation effects
Anus Neoplasms pathology
Anus Neoplasms therapy
Carcinoma, Squamous Cell pathology
Carcinoma, Squamous Cell therapy
Chemoradiotherapy
Clinical Trials, Phase III as Topic
Combined Modality Therapy
Fluorouracil administration & dosage
Humans
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Anus Neoplasms drug therapy
Anus Neoplasms radiotherapy
Carcinoma, Squamous Cell drug therapy
Carcinoma, Squamous Cell radiotherapy
Radiotherapy, Intensity-Modulated
Subjects
Details
- Language :
- English
- ISSN :
- 1558-5042
- Volume :
- 26
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Surgical oncology clinics of North America
- Publication Type :
- Academic Journal
- Accession number :
- 27889038
- Full Text :
- https://doi.org/10.1016/j.soc.2016.07.003